AI Protein Design Market to Reach $13.70 Billion by 2035 as Generative Models Reshape Drug Discovery
核心洞察
The AI Protein Design Market was valued at USD 1.58 billion in 2025 and is projected to reach USD 13.70 billion by 2035, growing at a 24.1% CAGR.
Drug Discovery & Therapeutics dominated applications with a 59.30% share in 2025, while De Novo Protein Generation is the fastest-growing technology segment at a 30.60% CAGR.
Isomorphic Labs (搜索) closed a USD 2.1 billion Series B round, and Chai Discovery (搜索) signed a licensing agreement with Pfizer for its de novo antibody design model Chai-3.
The AI Protein Design Market was valued at USD 1.58 billion in 2025 and is expected to reach USD 13.70 billion by 2035, growing at a compound annual growth rate (CAGR) of 24.1% from 2026 to 2035. The market is experiencing rapid growth as pharmaceutical, biotech, and industrial biotech firms adopt AI technologies alongside structural bioinformatics to design new protein molecules for therapeutic, catalytic, and agronomic applications. AI protein design platforms use deep learning techniques, including diffusion models, protein language models, and transformers, to predict the structure of novel proteins and predict binding affinity and developability. Such innovation in early drug discovery is reducing the time from target identification to a candidate from several years to just a few months at significantly reduced screening costs.
Generative Models Accelerate De Novo Protein Design
The De Novo Protein Generation market is projected to achieve the highest growth rate of 30.60% CAGR during the period of 2026-2035. This growth is driven by increased trust in generative diffusion and language-based models, which are capable of designing brand new binders, enzymes, and antibody frameworks independently of any existing templates. Successful pharmaceutical partnerships that prove the value of de novo-designed proteins during preclinical and early clinical development stages are encouraging companies to apply the benefits of generative design methods.
Structure Prediction & Modeling captured 36.80% of the revenue share in 2025, highlighting the significance of structural prediction in downstream protein engineering. Prediction models based on the AlphaFold (搜索) architecture are currently the standard choice in target validation, binding site determination, and candidate triage within pharmaceutical research and development pipelines.
Drug Discovery Leads Applications, Industrial Enzymes Grow Fastest
Drug Discovery & Therapeutics dominated the AI Protein Design Market, accounting for 59.30% market share in 2025, due to growing adoption of AI-based protein design solutions by pharma and biotech companies for rapid development of antibodies, peptides, and biologics for disease indications such as oncology, immunology, and rare diseases. Large milestone-based partnerships between AI-based technology platforms and pharmaceutical partners are further affirming the business potential of computationally-designed therapies.
The Industrial Enzymes & Biomanufacturing segment is expected to experience the highest CAGR of 29.40% during the forecast period, driven by the rising trend of using AI-designed enzymes to improve catalysis, thermodynamic stability, and substrate specificity in biofuel production, food processing, and specialty chemicals manufacturing.
Multi-Billion-Dollar Partnerships Validate the Platform
In 2026, Isomorphic Labs (搜索) closed a USD 2.1 billion Series B financing round led by Thrive Capital to extend its AlphaFold (搜索)-derived protein structure prediction platform beyond biologics into small-molecule and multi-modality drug design, reflecting intensifying investor confidence in AI-native protein engineering platforms.
Also in 2026, Chai Discovery (搜索) entered a licensing agreement with Pfizer granting the company early access to Chai-3, its generative model for de novo antibody design, alongside a custom biology model trained on Pfizer's proprietary discovery data. Additional notable deals include Genesis Molecular AI expanding its GEMS platform collaboration with Incyte in a deal valued at over USD 1 billion, and Dyno Therapeutics (搜索) entering a partnership with Roche worth up to USD 1.05 billion to apply its AI-designed AAV capsid engineering platform, CapsidMap, to next-generation gene therapy programs.
Regional Leadership and Growth Dynamics
North America accounted for a major 39.60% share of the world regional market in 2025, owing to clusters of native AI biotech companies, plentiful venture and pharmaceutical investment funds, and proximity to top structural biology academic institutions. The United States was the leading country within North America in 2025 with an 87.40% share of the regional market. The U.S. AI Protein Design Market was valued at USD 0.52 billion in 2025 and is projected to reach USD 4.36 billion by 2035, growing at a CAGR of 23.7%.
The Asia Pacific AI Protein Design Market is expected to witness the fastest growth rate during the forecast period 2026-2035, at a CAGR of 28.30%, driven by rapidly expanding biotechnology investment and growing government-backed AI and life sciences funding programs.
Market Drivers and Restraints
The rising integration of generative AI into pharmaceutical discovery, industrial enzyme engineering, and synthetic biology programs, combined with growing pharma-biotech partnership activity validating computationally designed candidates, are among the primary drivers of the market. AI protein design platforms provide a dramatically faster and more cost-effective alternative to traditional directed-evolution and crystallography-based protein engineering approaches, compressing discovery timelines from years to months while expanding access to previously undruggable target classes.
Among the most critical obstacles to market growth is the substantial computational infrastructure investment required to train and operate large-scale generative protein design models, which limits full-scale platform adoption among smaller biotechnology companies and academic research institutions lacking access to dedicated GPU compute resources. Moreover, the relatively limited number of AI-designed biologics that have progressed through late-stage clinical validation continues to create uncertainty among some pharmaceutical decision-makers regarding the translational reliability of computationally generated candidates.